Keros Therapeutics

Keros Therapeutics

Keros Therapeutics launched in 2015, emerging from the discovery that controlled modulation of transforming growth factor-beta (TGF-beta) ligands could address the root causes of hematologic and musculoskeletal diseases. Founder Jasbir Seehra, a biochemist who previously held senior roles at Acceleron Pharma, structured the company around protein therapeutics engineered to bind specific TGF-beta family members without the off-target toxicities that derailed earlier industry attempts. The founding scientific insight — targeting activin receptor type IIA and IIB signaling — shaped a pipeline now centered on rare blood disorders and cardiovascular disease. Keros' most advanced program is KER-050, or elritercept, an activin receptor type IIA-Fc fusion protein designed to treat cytopenias by promoting late-stage red blood cell and platelet production. It is in Phase 2 trials for myelodysplastic syndromes and myelofibrosis, including a registrational trial initiated in 2023 for transfusion-dependent anemia. A second candidate, KER-012, targets activin receptor type IIB to reduce the elevated TGF-beta signaling that drives vascular remodeling in pulmonary arterial hypertension, with Phase 2 data expected in 2025. The pipeline also includes KER-065, a dual inhibitor of activin A and myostatin, in Phase 1 for Duchenne muscular dystrophy and obesity-related muscle loss. Keros operates discovery and clinical operations from its Lexington, Massachusetts headquarters. In December 2021, the company entered a licensing agreement with Hansoh Pharmaceutical Group for development and commercialization across Greater China, securing an upfront payment and potential milestones exceeding $1 billion. The company reported 166 full-time employees at year-end 2023 and has funded operations through public equity offerings and the Hansoh partnership rather than private venture rounds. Its 2020 IPO on Nasdaq raised $96 million, followed by a $160 million follow-on offering in February 2023 that extended the cash runway into 2027. Keros is not a family office, fund, or asset allocator — it is a clinical-stage biopharmaceutical company that raises capital through equity markets and partnership agreements, with R&D expense representing the primary use of proceeds. Founder Seehra and the scientific leadership maintain deep ties to the Dana-Farber Cancer Institute and the broader Boston biotech ecosystem where the original TGF-beta biology was elucidated. Keros occupies a specific structural niche in TGF-beta drug development: while large pharmaceutical companies have largely abandoned broad TGF-beta inhibition due to cardiac toxicity, Keros' approach targets individual ligands with engineered Fc-fusion proteins that act as decoy receptors rather than blocking antibodies. This ligand-trap architecture, developed by Seehra and his co-founders from Acceleron, offers a cleaner selectivity profile than predecessor molecules. The company has not established related investment vehicles or philanthropic foundations separate from its corporate structure, and its governance follows a standard public-company model with a five-member board that included CEO Seehra and representatives from Orbimed Advisors and Foresite Capital at the time of the company's IPO.